

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		Attorney Docket No. <b>4301-1156</b> U.S. App. No. <b>10/1567774</b>
INTERNATIONAL APPLN. NO. <b>PCT/AT2004/000279</b>	INTERNATIONAL FILING DATE <b>August 9, 2004</b>	PRIORITY DATE CLAIMED <b>August 14, 2003</b>
TITLE OF INVENTION: <b>STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS</b>		
APPLICANT(S) FOR DO/EO/US: <b>Thomas SZEKERES, Norbert HANDLER, Walter JAGER, Arkadiusz Marek MURIAS and Thomas ERKER</b>		
Applicant herewith submits to the United States Designated Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)).                The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2))               <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau. See attached PCT/IB/308.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2))               <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))               <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made, however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))</li> <li>10. <input type="checkbox"/> A Declaration of Inventorship for purposes of U.S.A. designation pursuant to rule 4.17(iv). ))</li> <li>11. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol> <p><b>Items 12 to 23 below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS) w/PTO-1449 - <input type="checkbox"/> Copy of IDS citations. - <input checked="" type="checkbox"/> PCT/ISA/210 International Search Report included</li> <li>13. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s)).</li> <li>14. <input type="checkbox"/> A preliminary amendment.</li> <li>15. <input checked="" type="checkbox"/> An Application Data Sheet under 37 C.F.R. 1.76.</li> <li>16. <input checked="" type="checkbox"/> Itemized Return Receipt Postcard</li> <li>17. <input type="checkbox"/> Abstract</li> <li>18. <input type="checkbox"/> A substitute specification.</li> <li>19. <input type="checkbox"/> Power of Attorney and Statement under 37 CFR §3.73(b)               <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> Newly executed Power of Attorney</li> <li>b. <input type="checkbox"/> A change of Power of Attorney and/or change of address letter.</li> </ol> </li> <li>20. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</li> <li>21. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>22. <input type="checkbox"/> A second copy of the English language translation of the international application (35 U.S.C. 154(d)(4)).</li> <li>23. <input type="checkbox"/> Other items or information: <b><u>Please note that the Declaration of Inventorship for purposes of the U.S.A. designation pursuant to rule 4.17 (iv) was filed in the International Phase, see the published application.</u></b></li> </ol>		

U.S. APPLICATION NO. <b>10/567774</b>		INTERNATIONAL APPLN. NO. PCT/AT2004/000279		ATTORNEY DOCKET NO. 4301-1156	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input checked="" type="checkbox"/> The following fees are submitted:  <div style="text-align: center; margin-top: 10px;"><b>PCT FEES - NATIONAL STAGE</b></div>				<b>CALCULATIONS</b> PTO USE ONLY	
<u><b>Fee Description</b></u>					
Basic National Stage Fee				<b>\$300.00</b>	
Non ISA/US Search Provided      National Stage Search Fee				<b>\$400.00</b>	
<input type="checkbox"/> US was the IPEA And all claims satisfied the provisions of PCT Article 33 (1)-(4)      National Stage Examination Fee				<b>\$200.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20- <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (Fee Code 1617/2617)				<b>\$130.00</b>	
<b>National Stage Application</b> size fee each additional 50 sheets in excess of 100  Fee Code 1681/2681	<b>Additional Sheets</b> 22 - 100 =      =      X <div style="margin-left: 100px;">50</div>		<b>Fee From Below</b> <b>\$125.00</b>	<b>\$0.00</b>	
<b>CLAIMS</b>			NUMBER FILED	NUMBER EXTRA	RATE
Independent Claims    Fee Codes 1614 / 2614			1 - 3 =		x \$100.00
Total Claims      Fee Codes 1615 / 2615			30 - 20 =	10	x \$50.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable) Fee Code 1616 / 2616					+ \$360.00
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). Fee Code 1618				<b>\$130.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). (Fee code 8021) <div style="text-align: right;"><b>\$40.00</b> per property      +</div>				<b>\$0.00</b>	
<b>TOTAL FEES ENCLOSED      =</b>				<b>\$1,660.00</b>	
				Amount to be refunded:	\$
				Charged:	\$
<input checked="" type="checkbox"/> A check in the amount of <b>\$1,660.00</b> to cover the above fees is attached.  <input type="checkbox"/> The Director is hereby authorized to charge indicated fees and credit any overpayment to Deposit Account No. 25-0120 in the name of Young & Thompson. A duplicate copy of this sheet is enclosed.  <input checked="" type="checkbox"/> The Director is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17.					
SEND ALL CORRESPONDENCE TO: YOUNG & THOMPSON 745 South 23 <sup>rd</sup> Street Arlington, VA 22202 Telephone: (703) 521-2297 Facsimile: (703) 685-0573			<div style="margin-top: 20px;"></div> SIGNATURE		
			Benoit Castel, Reg. No. 35,041 NAME, REGISTRATION NUMBER		
Y&T Customer No. <b>00466</b>			February 9, 2006		
BC/yr			DATE		